Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PDUFA V ‘Program’ Gets Positive Evaluation – Except For Inspections

This article was originally published in The Pink Sheet Daily

Executive Summary

Longer application review time has been producing the improved communication sponsors expected, but modifications to the user fee program have yet to make inspections go smoother.


Related Content

US FDA's Inspection Decisions To Be Swayed By Facility "History" With Foreign Regulators
Sponsor-FDA Communications In IND Phase Will Get Outside Review
Inspection Delays Remain For Novel Approvals By US FDA; Will Quality Office Help?
PDUFA V 'Program' First-Cycle Approval Rates Significantly Higher For All Applications
FDA Breakthrough Troubles Emerge In Effort To Speed Development
PhRMA, BIO’s PDUFA V Application Tracker Could Inform “Course Corrections”
Buying Time: Industry Sacrifices Early To Gain Later With PDUFA V Review Model
Late-Cycle Approval Predictions Not A Good Idea, FDA Says
PDUFA V: Review Model Evaluators Will Observe All FDA-Sponsor Meetings





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts